PDS Biotechnology Corporation (PDSB)

Market Cap	263.85M
Revenue (ttm)	n/a
Net Income (ttm)	-42.04M
Shares Out	30.82M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,172,480
Open	8.60
Previous Close	6.72
Day's Range	7.32 - 8.92
52-Week Range	2.89 - 13.65
Beta	1.87
Analysts	Strong Buy
Price Target	18.25 (+113.2%)
Earnings Date	May 15, 2023

About PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treat...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Frank K. Bedu-Addo Ph.D.
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: PDSB

Analyst Forecast

According to 4 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is $18.25, which is an increase of 113.20% from the latest price.

Price Target

$18.25

(113.20% upside)

Analyst Consensus: Strong Buy